title: MiR-210: A potential therapeutic target against radiation-induced enteropathy.
abstract: A previously undescribed and robust miR210 overexpression is shown in intestinal samples obtained from patients with radiation enteropathy and fibrotic cultured cells. In addition, miR-210 overexpression is repressed by antifibrotic treatment combining pentoxifylline and α-tocopherol.
authors.affiliation: INSERM U-1030 "Molecular Radiotherapy", Institut Gustave Roussy, Villejuif, France; LabEX LERMIT Villejuif, France; Université Paris Sud Paris XI, Le Kremlin Bicêtre, France. Electronic address: saad.hamama@igr.fr.
authors.forename: Saad
authors.initials: S
authors.lastname: Hamama
authors.affiliation: INSERM, U753, Laboratoire d'immunologie des Tumeurs Humaines: Interaction Effecteurs Cytotoxiques-Système Tumoral, Institut Gustave-Roussy, Villejuif, France. Electronic address: muhammed-zaeem.noman@igr.fr.
authors.forename: Muhammad Zaeem
authors.initials: MZ
authors.lastname: Noman
authors.affiliation: Geneva University Hospital and Medical School, Geneva, Switzerland. Electronic address: pascal.gervaz@lacolline.ch.
authors.forename: Pascal
authors.initials: P
authors.lastname: Gervaz
authors.affiliation: Unité de Radiopathologie, Service Oncologie-Radiothérapie, Hôpital Saint-Louis, APHP, Paris, France. Electronic address: sylvie.delanian@sls.aphp.fr.
authors.forename: Sylvie
authors.initials: S
authors.lastname: Delanian
authors.affiliation: INSERM U-1030 "Molecular Radiotherapy", Institut Gustave Roussy, Villejuif, France; LabEX LERMIT Villejuif, France; Université Paris Sud Paris XI, Le Kremlin Bicêtre, France; Laboratoire de RadioOncologie, Swiss Cancer Center of Lausanne, CHUV, Lausanne, Switzerland. Electronic address: marie-catherine.vozenin@chuv.ch.
authors.forename: Marie-Catherine
authors.initials: MC
authors.lastname: Vozenin
mesh_terms: D000975:Antioxidants / Q000627:therapeutic use; D002478:Cells, Cultured / Q000187:drug effects / Q000378:metabolism; D004359:Drug Therapy, Combination; D005355:Fibrosis / Q000188:drug therapy / Q000378:metabolism; D006801:Humans; D000860:Hypoxia / Q000378:metabolism; D007410:Intestinal Diseases / Q000188:drug therapy* / Q000378:metabolism; D035683:MicroRNAs / Q000037:antagonists & inhibitors / Q000378:metabolism*; D058990:Molecular Targeted Therapy / Q000379:methods; D032389:Myocytes, Smooth Muscle / Q000187:drug effects / Q000378:metabolism; D010431:Pentoxifylline / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D012313:RNA / Q000378:metabolism; D000077278:RNA, Mitochondrial; D011832:Radiation Injuries / Q000188:drug therapy* / Q000378:metabolism; D011837:Radiation-Protective Agents / Q000627:therapeutic use*; D011878:Radiotherapy / Q000009:adverse effects; D024502:alpha-Tocopherol / Q000627:therapeutic use
chemical_list: D000975:Antioxidants; C543800:MIRN210 microRNA, human; D035683:MicroRNAs; D010975:Platelet Aggregation Inhibitors; D000077278:RNA, Mitochondrial; D011837:Radiation-Protective Agents; D012313:RNA; D024502:alpha-Tocopherol; D010431:Pentoxifylline
keywords: Anti-fibrotic treatment; Pentoxifylline; Radiation enteropathy; Radiation-induced fibrosis; Trolox; microRNA miR-210